Clinical Trial Update: Intravenous Human IgG1 Fc Fragment (Efgartigimod) in Myasthenic Crisis [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating intravenous efgartigimod for myasthenic crisis; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myasthenia Gravis

Drugs mentioned

• Efgartigimod (efgartigimod)

Snippet

Sponsor: Rambam Health Care Campus | Conditions: Myasthenia Gravis Crisis | Phase 4 | Status: NOT_YET_RECRUITING